Mettl3-mediated m<sup>6</sup>A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and osteoporosis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30429466.
- Also identified by DOI 10.1038/s41467-018-06898-4 and PMC identifier 6235890.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) is the most abundant epigenetic modification in eukaryotic mRNAs and is essential for multiple RNA processing events during mammalian development and disease control. Here we show that conditional knockout of the m<sup>6</sup>A methyltransferase Mettl3 in bone marrow mesenchymal stem cells (MSCs) induces pathological features of osteoporosis in mice. Mettl3 loss-of-function results in impaired bone formation, incompetent osteogenic differentiation potential and increased marrow adiposity. Moreover, Mettl3 overexpression in MSCs protects the mice from estrogen deficiency-induced osteoporosis. Mechanistically, we identify PTH (parathyroid hormone)/Pth1r (parathyroid hormone receptor-1) signaling axis as an important downstream pathway for m<sup>6</sup>A regulation in MSCs. Knockout of Mettl3 reduces the translation efficiency of MSCs lineage allocator Pth1r, and disrupts the PTH-induced osteogenic and adipogenic responses in vivo. Our results demonstrate the pathological outcomes of m<sup>6</sup>A mis-regulation in MSCs and unveil novel epitranscriptomic mechanism in skeletal health and diseases.
Medical subject headings
- Mesenchymal Stem Cells
- Methyltransferases
- Osteoporosis
- RNA, Messenger